Welcome to our dedicated page for American Superconductor SEC filings (Ticker: AMSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding American Superconductor’s filings can feel like untangling three businesses at once—wind-turbine electronics, grid reliability gear, and ship-protection systems each live in separate footnotes. If you are searching for “American Superconductor insider trading Form 4 transactions” or trying to compare backlog disclosures across segments, hundreds of pages stand between you and clarity.
Stock Titan removes that barrier. Our AI reads every new document the moment it posts to EDGAR, turning a dense 10-K into a plain-English brief and flagging the line items investors track most. Need the “American Superconductor quarterly earnings report 10-Q filing”? It arrives with ratios, segment margins, and contract updates already highlighted. Real-time alerts surface “American Superconductor Form 4 insider transactions real-time”, so you see executive stock moves before the market digests them. We also link each 8-K headline—turbine order, Navy contract, or grid pilot—to the exact paragraph where management explains the material event.
Whether you are “understanding American Superconductor SEC documents with AI” or performing deeper “American Superconductor earnings report filing analysis,” every form is covered:
- “American Superconductor annual report 10-K simplified” for segment risk, export controls, and R&D spend
- “American Superconductor proxy statement executive compensation” to evaluate incentive alignment
- “American Superconductor 8-K material events explained” within minutes of release
- “American Superconductor executive stock transactions Form 4” with sortable history
Save hours locating revenue by market, monitoring contract wins, and spotting insider sentiment. Complex filings made clear—so you can focus on decisions, not documentation.
Transaction close: On August 3, 2025 E2open Parent Holdings, Inc. (“E2open”) and E2open Holdings, LLC completed their previously announced merger with WiseTech Global Ltd. All outstanding Class A, B-1 and vested B-2 common shares and eligible Holdings units were cancelled for $3.30 cash; non-economic Class V shares and WiseTech-owned units were extinguished without consideration. E2open now operates as a wholly owned WiseTech subsidiary.
Key closing effects:
- NYSE trading halted before the August 4 open; Form 25 to delist and Form 15 to end SEC registration will follow.
- 2021 Credit Agreement fully repaid and terminated, eliminating outstanding loans and commitments.
- Public warrants now exercisable for the $3.30 cash price; warrant price temporarily cut to $3.2947 until September 3 2025, after which unexercised warrants will be cancelled.
- Board replaced by WiseTech appointees; CEO Andrew Appel and CFO Marje Armstrong step down but remain for transition and share in an $8.975 m transaction-bonus pool.
- Certificate of incorporation and bylaws amended; change-in-control completed.
StoneX Group Inc. (SNEX) – Form 4 insider activity
Director John M. Fowler reported the award of 139 restricted common shares on 31 Jul 2025 (transaction code “A”) under the company’s Restricted Stock Program. The grant carries no cash price and will vest in three equal annual tranches. After the transaction Fowler now directly owns 116,874 SNEX shares and indirectly holds 3,000 shares through his spouse.
No sales, options, or other derivative transactions were disclosed. While the filing reflects continued insider alignment, the incremental shares represent less than 0.5 % of his current stake and are unlikely to be material to StoneX’s equity structure.
UroGen Pharma Ltd. (URGN) submitted a Form 4 showing that Chief Executive Officer Elizabeth A. Barrett acquired 87,615 performance stock units (PSUs) on 07/28/2025. The PSUs were originally granted on 01/31/2024 and became earned when a company-level milestone was reached. Each PSU entitles the holder to one ordinary share once the units vest on 12/31/2025, contingent upon Barrett’s continued employment. The award carries a $0 exercise price and no shares were sold or otherwise disposed of in the filing.
Post-transaction, the CEO directly holds 87,615 derivative securities representing potential ordinary shares; no changes were reported in her non-derivative share ownership. While the filing signals management’s alignment with performance goals, it also introduces a future dilution overhang equivalent to the underlying shares when they convert.
Kiniksa Pharmaceuticals International, plc (KNSA) has filed a Form 144 to notify the SEC of an intended insider sale.
- Shares to be sold: 64,508 common shares
- Aggregate market value: $1,928,595.68
- Approximate sale date: 07/30/2025
- Broker: Morgan Stanley Smith Barney LLC, New York
- Shares outstanding: 74,107,668
The shares were acquired the same day (07/30/2025) through the exercise of employee stock options under a registered plan and will be sold for cash. No other sales by this insider were reported in the past three months.
The proposed disposition equals roughly 0.09% of total shares outstanding, indicating a modest, routine-sized transaction rather than a large liquidation. The filer attests to having no undisclosed material adverse information and confirms compliance with Rule 10b5-1.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has filed Post-Effective Amendment No. 1 to four previously effective Form S-8 registration statements. The company is deregistering all unsold shares that had been reserved for issuance under its 2018, 2019 and 2023 equity compensation and ESPP plans. The action follows shareholder approval on 29 Jul 2025 of both (1) an Asset Purchase Agreement with Gilead Sciences covering what may be substantially all of HOOKIPA’s assets and (2) a Plan of Dissolution. As the company now intends to liquidate and dissolve, it is terminating any further offerings under the affected registration statements and removing from registration the remaining shares (no reverse-split adjustment applied in counts).
The filing contains no financial results, but it confirms the end of HOOKIPA’s equity incentive programs and signals that the company will wind down operations once the asset sale closes and dissolution begins. There is no impact on outstanding shares already issued; the amendment solely affects unsold, unissued shares registered for future employee grants. Management states the filing satisfies the undertaking in Part II of each S-8 to remove such securities upon termination of the offerings.
FAQ
What is the current stock price of American Superconductor (AMSC)?
What is the market cap of American Superconductor (AMSC)?
What are the core business segments of AMSC?
How does AMSC enhance the efficiency of wind energy?
What role does Gridtec play in AMSC’s offerings?
How does AMSC contribute to defense and marine applications?
What makes AMSC’s technology innovative?
What is the geographic reach of AMSC?
How does AMSC maintain its competitive edge?
Can you explain AMSC’s business model?
